Clinical Research Fellow
Centre for Haemato-Oncology
Clinical Specialty: Haematology

We would like to demonstrate that BTK inhibitors like Ibrutinib or ACP-196 have the potential to decrease PD-1 expression on T-cells and PD-L1 expression on B-cells in CLL patients and therby have the ability to repair T-cell defects commonly observed in CLL.

We aim to develop a combinatory approach of using BTK-inhibitors and PD-1 immune checkpoint blockade in the TCL-1 mouse model of CLL as a basis to investigate similar approaches in CLL-patients.

See other researchers working on:

Blood cancers Immunology Leukaemia
This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.